Challenges in cancer vaccine development for hepatocellular carcinoma
Challenges in cancer vaccine development for hepatocellular carcinoma
复制标题
DOI：
10.1016/j.jhep.2013.05.031
复制
发表时间：
2013-10-01
影响因子：
25.7
通讯作者：
Buonaguro, Franco M.
中科院分区：
文献类型：
--
作者：
Buonaguro, Luigi;Petrizzo, Annacarmen;Buonaguro, Franco M.
肝细胞癌（Hepatocellular carcinoma，HCC）是最常见的肝脏恶性肿瘤，在全世界男性和女性中分别是第三和第五大癌症死亡原因。HCC发生的主要危险因素是B和丙型肝炎病毒（HBV和HCV）感染;例如，在一个实施例中，酒精中毒和黄曲霉毒素）是额外的危险因素。由于现有治疗的低有效性，HCC预后通常较差，总体5年生存率约为5-6%.In此框架下，免疫干预，包括癌症疫苗，可能代表一种新的和有效的治疗工具。然而，迄今为止，仅进行了少数针对HCC的免疫治疗试验，其结果相反，这表明需要在免疫治疗方法的几个方面进行改进。新的特异性肿瘤抗原的鉴定和最先进的组合策略的评估可能会导致前所未有的临床结果，对HCC患者具有巨大的有益效果。和未来的前景报告在本审查。(C)2013年欧洲肝脏研究协会。由Elsevier B出版。V.保留所有权利。
Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively.The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e. g., alcoholism and aflatoxin) are additional risk factors.HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5-6%.In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented.In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients.The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.